Q-omics provides the consensus-scored TMEM202 profile across patient tissues and cancer cell-line models. TMEM202 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM202 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, TMEM202 RNA expression shows 7,970 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where TMEM202 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM202 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM202 survival associations across molecular data types. TMEM202 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM202 RNA expression–survival associations across cancer types. High TMEM202 expression shows unfavorable associations in KIRP, BLCA and READ, but favorable associations in ESCA, UCS and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .034). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM202 RNA expression.
This table summarizes TMEM202 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM202. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM202 shows higher tumor expression in HNSC, LIHC and LUSC. The HNSC box plot shows higher TMEM202 RNA expression in tumor versus normal tissue (log2 FC = +0.119, t-test p = .018).
This table shows molecular features associated with TMEM202 in patient tissues and cancer cell lines. In patient samples, TMEM202 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM202 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
